Henaux S, et al. - This study entailed analysis of evidence comparing biological disease-modifying antirheumatic drugs (bDMARDs) discontinuation/tapering vs continuation in rheumatoid arthritis (RA) patients with remission or low disease activity (LDA), focusing on the risk of losing remission, LDA or radiographic progression. An increased risk of losing remission or LDA and radiographic progression were documented as the consequences of bDMARDs discontinuation, while tapering did not increase the risk of relapse (LDA) or radiographic progression, even though there was an increased risk of losing remission.